文献速递姑息放疗与转移瘤

地塞米松预防骨转移姑息放疗后疼痛加剧:多中心双盲三臂随机DEXA研究

Dexamethasone for the Prevention of a Pain Flare After Palliative Radiation Therapy for Painful Bone Metastases: The Multicenter Double-Blind Placebo-Controlled 3-Armed Randomized Dutch DEXA Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-05-22

该双盲随机安慰剂对照试验纳入295例实体瘤骨转移疼痛患者,比较两种地塞米松方案与安慰剂预防放疗后疼痛加剧。

要点

  • 地塞米松推迟疼痛加剧发生时间并降低第2-5天疼痛评分
  • 三组不良反应相似

核心结论

  • 无充分证据表明地塞米松可降低放疗诱导的疼痛加剧发生率。
  • 地塞米松推迟了疼痛加剧的发生并降低第2-5天平均疼痛评分。

研究设计与样本

  • 多中心双盲随机安慰剂对照三臂试验,2012年1月至2016年4月随机295例实体瘤骨转移疼痛患者。
  • A组放疗前8 mg地塞米松后每日3次地塞米松;B组8 mg地塞米松后每日3次安慰剂;C组4次安慰剂。
  • 主要分析为意向性治疗,缺失数据归类为发生疼痛加剧。

主要发现

  • B组疼痛加剧发生率最低但较高比例未恢复至基线疼痛水平,提示疼痛进展。

关键数值与推荐

  • 疼痛加剧定义:0-10分疼痛评分增加至少2分且阿片类药物摄入未减少,或阿片类药物摄入增加25%及以上且疼痛评分未降低,随后恢复至基线或更低。
  • 地塞米松方案:放疗前8 mg,后续每日3次(A组全程地塞米松,B组后续安慰剂)。

临床怎么用

  • 地塞米松不能显著预防疼痛加剧发生,但可推迟发生时间并降低放疗后早期(第2-5天)疼痛评分。
  • 对接受骨转移姑息放疗的患者,可考虑地塞米松以减轻早期疼痛加重,但需权衡缺乏发生率获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: After radiation therapy for painful bone metastases, up to 44% of patients report a pain flare (PF). Our study compared 2 dose schedules of dexamethasone versus placebo to prevent PF. METHODS AND MATERIALS: This double-blind, randomized, placebo-controlled trial allocated patients with painful bone metastases from solid tumors randomly to receive 8 mg dexamethasone before radiation therapy followed by 3 daily doses (group A), 8 mg dexamethasone followed by 3 doses of placebo (group B), or 4 doses of placebo (group C). Patients reported worst pain scores, study medication side effects, and opioid intake before treatment and thereafter daily for 14 days and on day 28. PF was defined as at least a 2-point increase on a 0 to 10 pain scale with no decrease in opioid intake or a 25% or greater increase in opioid intake with no decrease in pain score, followed by a return to baseline or lower. The primary analysis was by intention to treat with patients who had missing data classified as having a PF. RESULTS: From January 2012 to April 2016, 295 patients were randomized. PF incidence was 38% for group A, 27% for group B, and 39% for group C (P = .07). Although patients in group B had the lowest PF incidence, a relatively high percentage did not return to baseline pain levels, indicating pain progression. The mean duration of PF was 2.1 days for group A, 4.5 days for group B, and 3.3 days for group C (P = .0567). Dexamethasone postponed PF occurrence; in group A 52% occurred on days 2 to 5 versus 73% in group B and 99% in group C (P = .02). Patients in group A reported lower mean pain scores on days 2 to 5 than those in group B or C (P < .001). Side effects were similar. CONCLUSIONS: There was insufficient evidence that dexamethasone reduced the incidence of radiation-induced PF. However, dexamethasone postponed the occurrence of PF and led to lower mean pain scores on days 2 to 5.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. van der Linden YM, Westhoff PG, Stellato RK, et al. Dexamethasone for the Prevention of a Pain Flare After Palliative Radiation Therapy for Painful Bone Metastases: The Multicenter Double-Blind Placebo-Controlled 3-Armed Randomized Dutch DEXA Study. Int J Radiat Oncol Biol Phys. 2020. PMID: 32446951. doi:10.1016/j.ijrobp.2020.05.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。